Ocugen (OCGN) said Wednesday that the US Food and Drug Administration had lifted the clinical hold on its investigational new drug application for the phase 1 trial of its experimental drug, OCU200, a recombinant fusion protein used to treat diabetic macular edema.
The company said it also plans to explore additional uses for OCU200, including potentially treating diabetic retinopathy and wet age-related macular degeneration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.